Autolus Therapeutics (NASDAQ:AUTL) Trading 4% Higher – Should You Buy?

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price was up 4% during trading on Friday . The stock traded as high as $3.18 and last traded at $3.13. Approximately 2,001,397 shares traded hands during trading, an increase of 39% from the average daily volume of 1,438,985 shares. The stock had previously closed at $3.01.

Analysts Set New Price Targets

A number of brokerages recently commented on AUTL. Needham & Company LLC reiterated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a report on Monday, November 11th. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $9.45.

Autolus Therapeutics Stock Up 2.3 %

The company has a market cap of $819.56 million, a PE ratio of -2.55 and a beta of 2.04. The stock has a 50-day moving average of $3.91 and a 200-day moving average of $3.99.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period last year, the firm earned ($0.26) EPS. Research analysts expect that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Institutional Trading of Autolus Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP boosted its stake in shares of Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after purchasing an additional 6,330,392 shares in the last quarter. FMR LLC increased its holdings in shares of Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after buying an additional 5,478,706 shares during the period. Avoro Capital Advisors LLC bought a new stake in shares of Autolus Therapeutics in the 1st quarter valued at about $78,765,000. Armistice Capital LLC boosted its holdings in Autolus Therapeutics by 33.8% during the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after acquiring an additional 1,578,000 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Autolus Therapeutics by 82.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after acquiring an additional 2,487,778 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.